A number of investment brokers have recently updated their price targets on shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).

Most recent broker ratings

04/29/2016 – Alexion Pharmaceuticals, Inc. had its “outperform” rating reiterated by analysts at Leerink Swann.

04/29/2016 – Alexion Pharmaceuticals, Inc. was upgraded to “outperform” by analysts at BMO Capital Markets. They now have a USD 168 price target on the stock.

04/26/2016 – Alexion Pharmaceuticals, Inc. had its “outperform” rating reiterated by analysts at Oppenheimer. They now have a USD 228 price target on the stock.

03/07/2016 – Alexion Pharmaceuticals, Inc. was downgraded to “neutral” by analysts at Robert W. Baird. They now have a USD 170 price target on the stock.

02/25/2016 – Citigroup began new coverage on Alexion Pharmaceuticals, Inc. giving the company a “neutral” rating. They now have a USD 165 price target on the stock.

02/04/2016 – Alexion Pharmaceuticals, Inc. had its “buy” rating reiterated by analysts at Stifel Nicolaus. They now have a USD 230 price target on the stock.

02/04/2016 – Alexion Pharmaceuticals, Inc. had its “hold” rating reiterated by analysts at Jefferies. They now have a USD 165 price target on the stock.

02/04/2016 – Alexion Pharmaceuticals, Inc. had its “neutral” rating reiterated by analysts at Goldman Sachs. They now have a USD 186 price target on the stock.

02/04/2016 – Alexion Pharmaceuticals, Inc. had its “buy” rating reiterated by analysts at Bank of America Merrill Lynch. They now have a USD 204 price target on the stock.

02/04/2016 – Alexion Pharmaceuticals, Inc. had its “buy” rating reiterated by analysts at UBS. They now have a USD 200 price target on the stock.

02/04/2016 – Alexion Pharmaceuticals, Inc. had its “equal-weight” rating reiterated by analysts at Barclays. They now have a USD 175 price target on the stock.

01/20/2016 – Credit Suisse began new coverage on Alexion Pharmaceuticals, Inc. giving the company a “neutral” rating. They now have a USD 201 price target on the stock.

01/07/2016 – Alexion Pharmaceuticals, Inc. was downgraded to “neutral” by analysts at BTIG Research.

01/06/2016 – SunTrust began new coverage on Alexion Pharmaceuticals, Inc. giving the company a “buy” rating. They now have a USD 225 price target on the stock.

01/04/2016 – Alexion Pharmaceuticals, Inc. had its “overweight” rating reiterated by analysts at Piper Jaffray. They now have a USD 221 price target on the stock.

The share price of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) was down -1.12% during the last trading session, with a day high of 143.52. 933231 shares were traded on Alexion Pharmaceuticals, Inc.’s last session.

The stock’s 50 day moving average is 145.73 and its 200 day moving average is 159.03. The stock’s market capitalization is 31.76B. Alexion Pharmaceuticals, Inc. has a 52-week low of 124.16 and a 52-week high of 208.88.

View other investors thoughts on Alexion Pharmaceuticals, Inc. with our new Stock Talk discussion platform. Sign up for free to contribute to the community and view research provided from other investors for any stock listed on the LSE, NYSE or NASDAQ.